Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN)

Q: What does CUSIP 29337E102 represent in this 13F holders report?

CUSIP 29337E102 is the security identifier for ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q4 2023?

61 institutional investors reported ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q4 2023. Use the holders table for investor-level position and value details.

CUSIP: 29337E102

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 58,923,077
Total 13F shares: 39,000,634
Share change: -77,951
Total reported value: $539,791,932
Price per share: $13.84
Number of holders: 61
Value change: -$652,659
Number of buys: 29
Number of sells: 20

Quarterly Holders Quick Answers

What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2024
Previous quarter: Q3 2023

Recent filing periods for CUSIP 29337E102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	15%	8,998,338	$122,917,297	—	30 Sep 2023	13F
5AM Venture Management, LLC	13F	Company	8.8%	5,160,975	$70,498,919	—	30 Sep 2023	13F
David P. Bonita	3/4/5	Director, 10%+ Owner	— mixed-class rows	4,207,568 mixed-class rows	$63,552,894	—	02 Jun 2022	3/4/5
FMR LLC	13F	Company	6.2%	3,676,213	$50,217,070	—	30 Sep 2023	13F
VR Adviser, LLC	13F	Company	5%	2,954,902	$40,363,961	—	30 Sep 2023	13F
Commodore Capital LP	13F 3/4/5	Company · 10%+ Owner	4.9%	2,901,816	$39,638,807	—	30 Sep 2023	13F 3/4/5
New Enterprise Associates 14, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,611,050	$39,518,242	—	05 Apr 2022	3/4/5
Mark Chin	3/4/5	Director	— mixed-class rows	2,352,572 mixed-class rows	$35,477,530	—	02 Jun 2022	3/4/5
RA CAPITAL MANAGEMENT, L.P.	3/4/5 13F	Former 10% owner · Company	3.6% from 13F	2,122,465	$32,123,508	—	23 Feb 2023	3/4/5 13F
CITADEL ADVISORS LLC	13F	Company	4%	2,351,491	$32,121,367	—	30 Sep 2023	13F
Braden M. Leonard	3/4/5	10%+ Owner	— class O/S missing	1,997,774	$30,236,309	—	03 Jan 2023	3/4/5
Fairmount Funds Management LLC	13F	Company	3.6%	2,131,369	$29,114,501	—	30 Sep 2023	13F
Barbara Dalton	3/4/5	Director	— mixed-class rows	1,566,222 mixed-class rows	$23,576,122	—	02 Jun 2022	3/4/5
BlackRock Finance, Inc.	13F	Company	2.7%	1,567,532	$21,412,487	—	30 Sep 2023	13F
Cormorant Asset Management, LP	13F	Company	2.1%	1,216,712	$16,620,286	—	30 Sep 2023	13F
VANGUARD GROUP INC	13F	Company	2%	1,151,817	$15,733,819	—	30 Sep 2023	13F
Frazier Life Sciences Management, L.P.	13F	Company	1.8%	1,050,483	$14,349,598	—	30 Sep 2023	13F
Carl Goldfischer	3/4/5	Director	— mixed-class rows	711,880 mixed-class rows	$10,645,656	—	02 Jun 2022	3/4/5
Boxer Capital, LLC	13F	Company	1.1%	646,058	$8,825,152	—	30 Sep 2023	13F
STATE STREET CORP	13F	Company	0.8%	470,852	$6,431,838	—	30 Sep 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.73%	432,972	$5,915,072	—	30 Sep 2023	13F
Woodline Partners LP	13F	Company	0.67%	395,686	$5,405,071	—	30 Sep 2023	13F
Logos Global Management LP	13F	Company	0.52%	307,076	$4,194,658	—	30 Sep 2023	13F
JANUS HENDERSON GROUP PLC	13F	Company	0.47%	276,416	$3,768,936	—	30 Sep 2023	13F
David M. Mott	3/4/5	Director	— mixed-class rows	237,724 mixed-class rows	$3,469,305	—	02 Jun 2022	3/4/5
NORTHERN TRUST CORP	13F	Company	0.33%	194,534	$2,657,334	—	30 Sep 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.27%	156,631	$2,139,579	—	30 Sep 2023	13F
HighVista Strategies LLC	13F	Company	0.21%	124,587	$1,701,858	—	30 Sep 2023	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.18%	103,600	$1,415,176	—	30 Sep 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.15%	86,967	$1,187,969	—	30 Sep 2023	13F
Bank of New York Mellon Corp	13F	Company	0.14%	80,759	$1,103,168	—	30 Sep 2023	13F
BML Capital Management, LLC	13F	Company	0.08%	50,000	$683,000	—	30 Sep 2023	13F
Swiss National Bank	13F	Company	0.07%	40,673	$555,593	—	30 Sep 2023	13F
Kenneth Attie	3/4/5	SVP, CMO	— mixed-class rows	68,200 mixed-class rows	$516,104	—	28 Jan 2022	3/4/5
RHUMBLINE ADVISERS	13F	Company	0.06%	34,363	$469,387	—	30 Sep 2023	13F
MORGAN STANLEY	13F	Company	0.06%	33,970	$464,031	—	30 Sep 2023	13F
Michael Gray	3/4/5	CFO & COO	— class O/S missing	27,610	$417,877	—	22 Feb 2023	3/4/5
JBF Capital, Inc.	13F	Company	0.05%	27,006	$368,902	—	30 Sep 2023	13F
JPMORGAN CHASE & CO	13F	Company	0.04%	26,495	$361,922	—	30 Sep 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.04%	23,106	$315,629	—	30 Sep 2023	13F
CREDIT SUISSE AG/	13F	Company	0.04%	22,850	$312,131	—	30 Sep 2023	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.04%	21,509	$293,813	—	30 Sep 2023	13F
Legal & General Group Plc	13F	Company	0.03%	19,665	$268,624	—	30 Sep 2023	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.03%	18,948	$258,830	—	30 Sep 2023	13F
Invesco Ltd.	13F	Company	0.03%	18,766	$256,343	—	30 Sep 2023	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.03%	17,950	$245,197	—	30 Sep 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.03%	17,690	$241,645	—	30 Sep 2023	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.02%	14,330	$195,748	—	30 Sep 2023	13F
BARCLAYS PLC	13F	Company	0.02%	13,629	$186,172	—	30 Sep 2023	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.02%	12,972	$177,198	—	30 Sep 2023	13F

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) as of Q4 2023

As of 31 Dec 2023, Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) was held by 61 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 39,000,634 shares. The largest 10 holders included ORBIMED ADVISORS LLC, FMR LLC, 5AM Venture Management, LLC, VR Adviser, LLC, COMMODORE CAPITAL LP, CITADEL ADVISORS LLC, Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., and VANGUARD GROUP INC. This page lists 61 institutional shareholders reporting positions in this security for the Q4 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 Value $	Q4 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.